[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619300":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":26,"studyPopulation":27,"armGroups":22,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":43,"responsibleParty":56,"collaborators":22,"id":58,"slug":22,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":22,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":22,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":81,"whyStopped":22,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Institute of Tropical Medicine, Belgium","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"Orthopoxvirus-specific serum binding and neutralising antibody titre","To describe the evolution of the orthopoxvirus-specific serum antibody response up to two years after MVA-BN booster vaccination","from enrollment to the end of follow up at 2 years",[14,18],{"measure":15,"description":16,"timeFrame":17},"Orthopoxvirus-specific systemic T- and B cell-mediated immune responses to MPXV","To describe the evolution of the orthopoxvirus-specific systemic cellular immune response up to two years after MVA-BN booster vaccination","from enrollment up to 2 years",{"measure":19,"description":20,"timeFrame":21},"MPXV-specific IgA in saliva and anorectal samples; T and B cell-mediated immune responses to MPXV, measured on saliva and anorectal samples","To describe the evolution of the orthopoxvirus-specific mucosal antibody \\& cellular immune response up to two years after MVA-BN booster vaccination","from enrolment up to two years",null,{"allocation":22,"interventionModel":22,"interventionModelDescription":22,"primaryPurpose":22,"observationalModel":24,"timePerspective":25,"maskingInfo":22},"COHORT","PROSPECTIVE","Mpox caused a worldwide outbreak in 2022 and continues to circulate worldwide and causes sporadic cases in Belgium and elsewhere. In the last 10 days, the first cases infected with the probably more virulent clade Ib MPXV have been reported from men who have sex with men in Belgium, the Netherlands, and elsewhere, indicating circulating this viral clade in sexual networks. In Belgium, vaccination against mpox was ceased at the end of 2022 and evidence showed that antibody levels against MPXV have decreased since then, raising questions about sustained protectiveness and the potential for a new mpox outbreak to emerge.\n\nPOQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.","Individuals who received MVA-BN booster vaccination will be asked to participate in \"POQS-Boosted\"",[29],{"name":30,"affiliation":31,"role":32},"Laurens Liesenborghs, MD","Institute of Tropical Medicine Antwerp","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":22,"email":38},"Christophe Van Dijck, PhD","CONTACT","+32 3 345 58 65","cvandijck@itg.be",{"name":40,"role":36,"phone":41,"phoneExt":22,"email":42},"Clinical Trials Unit Antwerp","+32 3 247 66 66","studies@itg.be",[44],{"facility":45,"status":22,"city":46,"state":22,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":22},"Institute of Tropical Medicine","Antwerp","2000","Belgium","BE",{"type":51,"coordinates":52},"Point",[53,54],4.40026,51.22047,{"lat":54,"lon":53},{"type":57,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100619300",false,"NCT07342829","Prospective Follow-up After MVA-BN Booster Vaccination","Prospective On-site Study for the Immunological Follow-up of Individuals Who Received Booster Vaccination With MVA-BN Against Mpox","POQS-Boosted","Inclusion Criteria:\n\n1. Is scheduled to receive a booster dose of MVA-BN\n2. ≥18 years\n3. Willingness to provide written informed consent\n4. Willingness to follow the study schedule\n\nExclusion Criteria:\n\n1\\. Past or current MPXV infection",true,"ALL","18 Years",{"count":69,"type":70},95,"ESTIMATED","2 Years","OBSERVATIONAL","POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.",[75],"Monkeypox (Mpox)",[77,78,79,80],"mpox","immunology","vaccination","booster","NOT_YET_RECRUITING","2026-01-15",{"date":84,"type":85},"2026-01-20","ACTUAL",{"date":82,"type":70},{"date":88,"type":70},"2028-06-30",{"name":5,"class":6},1]